

# Identification of Molecular Glue drug Candidates for PLK1 Degradation



ONCOLOGY	Candidate
Product Type	Targeted Protein Degradation
Indication	Triple-Negative Breast Cancer, TNBC
Target	Polo-like kinase 1 (PLK1)
MoA(Mechanism of Action)	Targeted Protein Degradation (Molecular glue degrader)
Competitiveness	<ul style="list-style-type: none"> <li>• PLK1 is frequently overexpressed in cancer and represents a highly validated and attractive therapeutic target.</li> <li>• AB410x is a first-in-class molecular glue degrader of PLK1, exhibiting strong anti-cancer efficacy across multiple tumor types, such as TNBC, AML, and mCRC.</li> <li>• PLK1 degraders demonstrate greater target selectivity compared to PLK1 inhibitors, suggesting a lower off-target toxicity.</li> </ul>
Development Stage	Candidate
Route of Administration	Oral Administration

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*